Blixeprodil vs Esketamine (CLE-100)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

Blixeprodil

Developed by Gilgamesh Pharma

Phase 2 in Major Depressive Disordersmall molecule
Weak signal

NCT06309277 · Phase 2 · completed

This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)

Result source: NCT06309277

Esketamine (CLE-100)

Developed by Clexio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT04103892 · Phase 2 · completed

The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)

Result source: NCT06340958

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBlixeprodilEsketamine (CLE-100)
MADRS, change (acute)-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

Blixeprodil
-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277
Esketamine (CLE-100)
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892

CGI-S, change (acute)

Blixeprodil
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS response

Blixeprodil
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS remission

Blixeprodil
—Not reported
Esketamine (CLE-100)
—Not reported

Relapse (% of patients)

Blixeprodil
—Not reported
Esketamine (CLE-100)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Blixeprodil: 2 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBlixeprodilEsketamine (CLE-100)
Dropout rate
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
7.7%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
8.3%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
0%210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
210 mg
time perception altered 63.2% (placebo 0%)
euphoric mood 57.9% (placebo 0%)
hallucination, visual 57.9% (placebo 0%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
140 mg
dizziness 46.5% (placebo 4.5%)
euphoric mood 44.2% (placebo 0%)
headache 37.2% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
140 mg
euphoric mood 61.1% (placebo 0%)
dizziness 50% (placebo 4.5%)
headache 50% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 30.8% (placebo 0%)
somnolence 15.4% (placebo 0%)
alanine aminotransferase increased 7.7% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
dizziness 13.9% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 11.1% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 18% (placebo 4.1%)
nausea 18% (placebo 0%)
headache 12% (placebo 2%)
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Blixeprodil's landscape · Esketamine (CLE-100)'s landscape